CL2011000941A1 - Composicion adecuada para la administracion oral a un animal que comprende una enzima reductora del estres inmunologico alfa-mananasa; y su uso para mejorar el rendimiento del crecimiento del animal y/o reducir el estres inmunologico del mismo (div. sol. n°3527-06). - Google Patents

Composicion adecuada para la administracion oral a un animal que comprende una enzima reductora del estres inmunologico alfa-mananasa; y su uso para mejorar el rendimiento del crecimiento del animal y/o reducir el estres inmunologico del mismo (div. sol. n°3527-06).

Info

Publication number
CL2011000941A1
CL2011000941A1 CL2011000941A CL2011000941A CL2011000941A1 CL 2011000941 A1 CL2011000941 A1 CL 2011000941A1 CL 2011000941 A CL2011000941 A CL 2011000941A CL 2011000941 A CL2011000941 A CL 2011000941A CL 2011000941 A1 CL2011000941 A1 CL 2011000941A1
Authority
CL
Chile
Prior art keywords
animal
stress
improve
oral administration
immune stress
Prior art date
Application number
CL2011000941A
Other languages
English (en)
Inventor
M Anderson David
Hsiao Humg-Yu
Liu Lin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2011000941A1 publication Critical patent/CL2011000941A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/244—Endo-1,3(4)-beta-glucanase (3.2.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C12N9/2494—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01006—Endo-1,3(4)-beta-glucanase (3.2.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01014—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01039—Glucan endo-1,3-beta-D-glucosidase (3.2.1.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01078—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICIÓN ADECUADA PARA LA ADMINISTRACIÓN ORAL A UN ANIMAL QUE COMPRENDE UNA ENZIMA REDUCTORA DEL ESTRÉS INMUNOLÓGICO EN UN VEHÍCULO ACEPTABLE PARA USO ORAL, DONDE DICHA COMPOSICIÓN SE SELECCIONA DEL GRUPO FORMADO POR: UN ALIMENTO PARA ANIMALES QUE COMPRENDE AL MENOS 20 UI ENZIMA / KG DE ALIMENTO, EN DONDE DICHA ENZIMA REDUCTORA DEL ESTRÉS INMUNOLÓGICO ES A-MANANASA; UNA COMPOSICIÓN LÍQUIDA DISTINTA DE UN ALIMENTO PARA ANIMALES QUE COMPRENDE AL MENOS 40.000 UI DE ENZIMA / L, EN DONDE DICHA ENZIMA REDUCTORA DEL ESTRÉS INMUNOLÓGICO ES A-MANANASA; Y UNA COMPOSICIÓN SÓLIDA DISTINTA DE UN ALIMENTO PARA ANIMALES QUE COMPRENDE AL MENOS 40.000 UI DE ENZIMA/KG, EN DONDE DICHA ENZIMA REDUCTORA DEL ESTRÉS INMUNOLÓGICO ES A-MANANASA; Y SU USO PARA MEJORAR EL RENDIMIENTO DEL CRECIMIENTO DEL ANIMAL Y/O REDUCIR EL ESTRÉS INMUNOLÓGICO DEL MISMO.
CL2011000941A 2005-12-15 2011-04-27 Composicion adecuada para la administracion oral a un animal que comprende una enzima reductora del estres inmunologico alfa-mananasa; y su uso para mejorar el rendimiento del crecimiento del animal y/o reducir el estres inmunologico del mismo (div. sol. n°3527-06). CL2011000941A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75033905P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
CL2011000941A1 true CL2011000941A1 (es) 2014-08-08

Family

ID=38218427

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000941A CL2011000941A1 (es) 2005-12-15 2011-04-27 Composicion adecuada para la administracion oral a un animal que comprende una enzima reductora del estres inmunologico alfa-mananasa; y su uso para mejorar el rendimiento del crecimiento del animal y/o reducir el estres inmunologico del mismo (div. sol. n°3527-06).

Country Status (35)

Country Link
US (5) US7914782B2 (es)
EP (2) EP1973561B1 (es)
JP (1) JP5189989B2 (es)
KR (2) KR101399205B1 (es)
CN (3) CN105831428B (es)
AR (1) AR057247A1 (es)
AT (1) ATE497779T1 (es)
AU (1) AU2006329927B2 (es)
BR (1) BRPI0620155B1 (es)
CA (1) CA2633066C (es)
CL (1) CL2011000941A1 (es)
CR (1) CR10116A (es)
DE (1) DE602006020074D1 (es)
DK (1) DK1973561T3 (es)
EC (1) ECSP088578A (es)
ES (1) ES2361819T3 (es)
GT (1) GT200600512A (es)
HN (1) HN2008000906A (es)
HR (1) HRP20080319B1 (es)
IL (2) IL192088A (es)
IN (1) IN2008DE06112A (es)
MX (1) MX284326B (es)
MY (1) MY145870A (es)
NO (1) NO340818B1 (es)
NZ (1) NZ569186A (es)
PE (1) PE20070840A1 (es)
PL (1) PL1973561T3 (es)
PT (1) PT1973561E (es)
RU (1) RU2465005C2 (es)
SI (1) SI1973561T1 (es)
SV (1) SV2008002942A (es)
TW (2) TWI402039B (es)
UA (1) UA95266C2 (es)
WO (1) WO2007075343A2 (es)
ZA (1) ZA200805780B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1973561T1 (sl) 2005-12-15 2011-07-29 Chemgen Corp Encimi, ki zmanjĺ ujejo imunski stres
WO2013122799A1 (en) * 2012-02-16 2013-08-22 Eli Lilly And Company Methods and compositions for reducing the environmental impact of animal waste
US20160183561A1 (en) * 2013-07-26 2016-06-30 Novozymes A/S Polypeptides having a-L-Galactosidase Activity and Polynucleotides Encoding Same
DK3119901T3 (da) * 2014-03-21 2021-07-26 Dsm Ip Assets Bv Fremgangsmåde til behanlding af gærcellevægge med en laminaripentaose-producerende beta-1,3-glucanase
CN106771257A (zh) * 2017-01-24 2017-05-31 北京美正生物科技有限公司 一种检测血清淀粉样蛋白a的酶联免疫吸附试剂盒及其制备方法和用途
CN107156522A (zh) * 2017-06-23 2017-09-15 都匀市山郎科技养殖有限公司 一种鸡饲料

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201949A (ja) * 1982-05-17 1983-11-25 Kyodo Shiryo Kk 家畜用配合飼料
US5372939A (en) * 1991-03-21 1994-12-13 The United States Of America As Represented By The United States Department Of Energy Combined enzyme mediated fermentation of cellulous and xylose to ethanol by Schizosaccharoyces pombe, cellulase, β-glucosidase, and xylose isomerase
JP2942384B2 (ja) * 1991-06-07 1999-08-30 株式会社ヤクルト本社 飼料効率改善添加剤
GB2261877A (en) * 1991-11-21 1993-06-02 Kyowa Hakko Kogyo Kk Animal feed additive comprising enzyme and amino acid
WO1995005455A1 (en) * 1993-08-13 1995-02-23 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
DK1142485T3 (da) * 1994-04-22 2008-06-02 Novozymes As Fremgangsmåde til forbedring af oplöseligheden af planteproteiner
GB9416841D0 (en) * 1994-08-19 1994-10-12 Finnfeeds Int Ltd An enzyme feed additive and animal feed including it
MY134684A (en) * 1995-05-15 2007-12-31 Gist Brocades Bv Application of phospholipases in animal feed
JP2001057852A (ja) * 1995-06-14 2001-03-06 Showa Denko Kk 耐熱酵素含有飼料用組成物
US5807694A (en) * 1995-09-07 1998-09-15 Economic Innovation And Technology Council, University Of Manitoba Detection of salmonella enteritidis and other pathogenic microorganisms and monoclonal antibody useful therefor
EP0862371B1 (en) * 1995-11-06 2002-05-08 Novozymes A/S Use of galactanase in animal feed
WO1997039114A1 (en) * 1996-04-12 1997-10-23 Novo Nordisk A/S AN ENZYME WITH β-1,3-GLUCANASE ACTIVITY
US6162473A (en) 1996-05-03 2000-12-19 Chemgen Corporation Hemicellulase use in feeds with low caloric content
CN1092495C (zh) 1996-05-03 2002-10-16 开姆根有限公司 半纤维素酶在低热焓饲料中的应用
US20020164751A1 (en) * 1996-06-19 2002-11-07 Short Jay M. Enzymes having thermostable phosphatase activity and methods of use thereof
GB9623539D0 (en) * 1996-11-12 1997-01-08 Biotal Ltd Enzymes and their use
GB2327345B (en) * 1997-07-18 1999-06-23 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for controlling bacterial infection
US6022566A (en) * 1997-12-02 2000-02-08 Balchem Corporation Method for increasing the feed intake, feed efficiency, daily gain and/or carcass grade in ruminants
EP0976838A1 (en) * 1998-05-06 2000-02-02 Rhone-Poulenc Nutrition Animale Enzymes mixture
US6331426B1 (en) * 1999-02-11 2001-12-18 Novozymes A/S Bacterial galactanases and use thereof
US6213930B1 (en) * 1999-03-15 2001-04-10 Wisconsin Alumni Research Foundation Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
US6500658B1 (en) * 1999-08-17 2002-12-31 Novozymes, A/S Xyloglucanase from Malbranchea
UA78486C2 (uk) * 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
GB0010748D0 (en) 2000-05-05 2000-06-28 Brown Paul D Tricep exercise horse (fold up and portable)
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
GB2371013B (en) 2001-01-16 2004-06-09 Terry John Claydon Copying apparatus
KR20040101889A (ko) * 2001-01-17 2004-12-03 라모트 앳 텔-아비브 유니버시티 리미티드 식충성 식물 유래의 키티나제, 이를 암호화하는폴리뉴클레오타이드 서열 및 이의 분리방법 및 사용방법
DE10105306A1 (de) * 2001-02-02 2002-08-22 Nutrinova Gmbh Futtermittel für die Nutztieraufzucht enthaltend Sorbinsäure und Enzyme
DE10105347A1 (de) 2001-02-05 2002-08-22 Nutrinova Gmbh Sorbinsäurepräparat enthaltend Probiotika als Futtermittelzusatz in der Nutztieraufzucht
IE20011100A1 (en) * 2001-12-21 2003-07-09 Vsl Pharma Ltd Analytical Method for Detecting Alkaline Sphingomyelinase and Kit for Use in Such Method
EP1471799A2 (en) * 2002-01-25 2004-11-03 DSM IP Assets B.V. Thermostable enzyme compositions
AU2003304239A1 (en) * 2002-11-13 2005-01-13 Yvonne J. Rosenberg A pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger
WO2004054609A1 (en) 2002-12-12 2004-07-01 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
AU2005210581B2 (en) * 2004-02-04 2010-06-24 Am-Pharma B.V. Use of alkaline phosphatase for the detoxification of LPS present at mucosal barriers
PL1740204T3 (pl) * 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
CN101208436B (zh) * 2005-03-25 2012-10-03 根特大学 类黄酮的酶促脱甲基化
CN1699576A (zh) * 2005-06-30 2005-11-23 江南大学 一种内切β－1,3葡聚糖酶基因及其克隆方法
EP1931332A4 (en) * 2005-09-12 2010-06-23 Zoltan Lab Llc COMPOUNDS AND COMPOSITIONS FOR CONTROLLING ABNORMAL CELL GROWTH
SI1973561T1 (sl) * 2005-12-15 2011-07-29 Chemgen Corp Encimi, ki zmanjĺ ujejo imunski stres
WO2009106368A1 (en) * 2008-02-29 2009-09-03 Gelato Corporation N.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases

Also Published As

Publication number Publication date
ES2361819T3 (es) 2011-06-22
IL192088A0 (en) 2009-02-11
AU2006329927B2 (en) 2011-09-29
US8778648B2 (en) 2014-07-15
PE20070840A1 (es) 2007-08-25
NZ569186A (en) 2011-09-30
CA2633066A1 (en) 2007-07-05
US20110171345A1 (en) 2011-07-14
US20110171344A1 (en) 2011-07-14
ECSP088578A (es) 2008-10-31
DE602006020074D1 (de) 2011-03-24
HRP20080319A2 (en) 2008-12-31
CR10116A (es) 2008-10-28
MX2008007735A (en) 2008-08-27
BRPI0620155B1 (pt) 2015-07-21
DK1973561T3 (da) 2011-05-23
SI1973561T1 (sl) 2011-07-29
CN101374544B (zh) 2016-05-18
US20110177195A1 (en) 2011-07-21
SV2008002942A (es) 2008-12-03
CN105831428B (zh) 2020-12-01
MY145870A (en) 2012-05-15
ZA200805780B (en) 2009-03-25
MX284326B (en) 2011-03-01
BRPI0620155A2 (pt) 2011-11-01
EP2263685A3 (en) 2011-04-06
UA95266C2 (uk) 2011-07-25
EP2263685A2 (en) 2010-12-22
EP1973561B1 (en) 2011-02-09
PL1973561T3 (pl) 2011-08-31
RU2008128583A (ru) 2010-01-20
US7914782B2 (en) 2011-03-29
CN105831428A (zh) 2016-08-10
NO20083035L (no) 2008-09-11
TWI619506B (zh) 2018-04-01
KR101399205B1 (ko) 2014-05-27
HN2008000906A (es) 2011-07-12
JP5189989B2 (ja) 2013-04-24
TWI402039B (zh) 2013-07-21
KR20080081972A (ko) 2008-09-10
CN101374544A (zh) 2009-02-25
JP2009519712A (ja) 2009-05-21
KR101454032B1 (ko) 2014-10-27
NO340818B1 (no) 2017-06-26
CA2633066C (en) 2015-01-20
IL192088A (en) 2013-07-31
IL227318A (en) 2016-11-30
WO2007075343A3 (en) 2007-10-04
US20170156371A1 (en) 2017-06-08
EP1973561A2 (en) 2008-10-01
KR20130082514A (ko) 2013-07-19
HRP20080319B1 (hr) 2015-11-20
AU2006329927A1 (en) 2007-07-05
WO2007075343A2 (en) 2007-07-05
GT200600512A (es) 2007-06-28
TW201336425A (zh) 2013-09-16
US20070141041A1 (en) 2007-06-21
ATE497779T1 (de) 2011-02-15
RU2465005C2 (ru) 2012-10-27
TW200731932A (en) 2007-09-01
PT1973561E (pt) 2011-05-12
AR057247A1 (es) 2007-11-21
IN2008DE06112A (es) 2008-09-26
CN102293323A (zh) 2011-12-28

Similar Documents

Publication Publication Date Title
CL2011000941A1 (es) Composicion adecuada para la administracion oral a un animal que comprende una enzima reductora del estres inmunologico alfa-mananasa; y su uso para mejorar el rendimiento del crecimiento del animal y/o reducir el estres inmunologico del mismo (div. sol. n°3527-06).
MX2007012591A (es) Composiciones que comprenden dos componentes y que son utiles como alimento para mascotas.
AR033439A1 (es) Composicion que comprende adyuvante prebiotico para disminuir procesos inflamatorios y activacion anormal de parametros no especificos inmunitarios
NO20074278L (no) Tigecyklinblandinger og fremgangsmater for fremstilling
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
CL2009001560A1 (es) Composición nutricional para bebes que comprende una mezcla de oligosacáridos compuesta de oligosacáridos n-acetilados, galactooligosácaridos y oligosacáridos sialilados; y su uso.
AR061614A1 (es) Bebidas proteicas acidificadas que contienen particulas en suspension y metodos para prepararlas
DK2468300T3 (da) Vaccinesammensætning indeholdende syntetisk adjuvant
WO2007117303A3 (en) Combination vaccine comprising an attenuated bovine viral diarrhea virus
AR058648A1 (es) Sistema abrasivo para composiciones de cuidado oral
EP4219560A3 (en) Integrin alpha v beta 8 neutralizing antibody
ATE481084T1 (de) Tensidhaltiges reinigungsmittel mit speziellen proteinen
AR033574A1 (es) Una cepa bacteriana del grupo de las bacterias lacticas capaces de reducir la tendencia de un individuo a desarrollar reacciones alergicas, las composiciones alimenticias y farmaceuticas que la contienen y las vacunas que la contienen
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
IL189400A (en) Compound comprising a combination of cellulose-3,1 (4) -andoglucanohydrolase, cellulose-3,1 (4) -glucan, soil containing disinfectant, mineral and glucomanin for use in enhancing innate immune function
BRPI0818718B8 (pt) processo de preparo de uma composição de vacina compreendendo antígeno e adjuvante na forma de látex inverso de homopolímero do ácido acrílico
NO20070351L (no) Materialer og fremgangsmater for forbedring av skalldyrhelse, -immunitet og -vekst
AR046187A1 (es) Uso de poli - alfa- 1,4- glucanos lineales como almidones resistentes
AR077832A1 (es) Metodo para suspender un flavonoide en una bebida
WO2022067233A3 (en) Canine antibody variants
TW200710224A (en) Attenuated avian infectious bronchitis virus vaccines
CL2008001778A1 (es) Formulacion liofilizada estable que comprende natalizumab, bufer con un ph entre 5,5 a 6,5, sacarosa y polisorbato; formulacion reconstituida estable; y metodo de preparacion.
CR20230531A (es) Composiciones de anticuerpos anti-tslp y usos de las mismas
AR056296A1 (es) Uso de vacuna de adn en combinacion con una vacuna convencional para vencer la interferencia de inmunogeno